APO Research
Talk to an analyst

APO RESEARCH · REPORT

α-Glucosidase Inhibitors

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global α-Glucosidase Inhibitors Market Outlook and Growth Opportunities 2026

20 December 2025219 pages

Choose your research edition.

Industry Researchα-Glucosidase Inhibitors Industry Research Report 2026149 pages · $2,950 USDIndustry Growth & TrendsGlobal α-Glucosidase Inhibitors Industry Growth and Trends Forecast to 2032125 pages · $3,450 USDMarket StructureGlobal α-Glucosidase Inhibitors Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032198 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal α-Glucosidase Inhibitors Market Outlook and Growth Opportunities 2026219 pages · $4,250 USDMarket Analysis & ForecastGlobal α-Glucosidase Inhibitors Market Analysis and Forecast 2026-2032210 pages · $4,950 USD

Market perspective

The global α-Glucosidase Inhibitors market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for α-Glucosidase Inhibitors is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for α-Glucosidase Inhibitors is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for α-Glucosidase Inhibitors is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the α-Glucosidase Inhibitors market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the α-Glucosidase Inhibitors market include Bluepharma, Glenmark Pharma, Lunan Pharma, Lupin Pharma, Strides Pharma, Bayer, Beijing SL Pharmaceutical, Cisen Pharmaceutical and Hangzhou East China Pharmaceutical, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global α-Glucosidase Inhibitors market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of α-Glucosidase Inhibitors and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents α-Glucosidase Inhibitors sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the α-Glucosidase Inhibitors market size, projected growth trends, production technologies, key applications, and end-use industries.

α-Glucosidase Inhibitors Segment by Company

Bluepharma

Glenmark Pharma

Lunan Pharma

Lupin Pharma

Strides Pharma

Bayer

Beijing SL Pharmaceutical

Cisen Pharmaceutical

Hangzhou East China Pharmaceutical

Pfizer

Jinri Pharmaceutical (China)

Livzon Pharm

Luye Pharma

Nanjing Hicin Pharmaceutical

Shandong New Time Pharmaceutical

CSPC Ouyi Pharmaceutical

Weiao Pharmaceutical (Sichuan)

Sun Pharmaceutical

SUN Pharma

Takeda

YaoPharma

Zhejiang Hisun Pharmaceutical

Zhejiang Jingxin Pharmaceutical

Zhejiang Medicine

α-Glucosidase Inhibitors Segment by Type

Acarbose

Voglibose

Miglitol

Other

α-Glucosidase Inhibitors Segment by Application

Hospital and Clinic

Pharmacy

Other

α-Glucosidase Inhibitors Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Nordic Countries

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global α-Glucosidase Inhibitors status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions α-Glucosidase Inhibitors market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify α-Glucosidase Inhibitors significant trends, drivers, influence factors in global and regions.

6. To analyze α-Glucosidase Inhibitors competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global α-Glucosidase Inhibitors market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of α-Glucosidase Inhibitors and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of α-Glucosidase Inhibitors.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the α-Glucosidase Inhibitors market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2021-2032).

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global α-Glucosidase Inhibitors industry.

Chapter 3: Detailed analysis of α-Glucosidase Inhibitors manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales and value of α-Glucosidase Inhibitors in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 7: Sales and value of α-Glucosidase Inhibitors in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. α-Glucosidase Inhibitors Industry Trends Table 2. α-Glucosidase Inhibitors Industry Drivers Table 3. α-Glucosidase Inhibitors Industry Opportunities and Challenges Table 4. α-Glucosidase Inhibitors Industry Restraints Table 5. Global α-Glucosidase Inhibitors Revenue by Company (US$ Million) & (2021-2026) Table 6. Global α-Glucosidase Inhibitors Revenue Share by Company (2021-2026) Table 7. Global α-Glucosidase Inhibitors Sales Volume by Company (K Units) & (2021-2026) Table 8. Global α-Glucosidase Inhibitors Sales Volume Share by Company (2021-2026) Table 9. Global α-Glucosidase Inhibitors Average Price (US$/Unit) of Company (2021-2026) Table 10. Global α-Glucosidase Inhibitors Company Ranking, (2024-2026) & (USD Million) Table 11. Global α-Glucosidase Inhibitors Key Company Manufacturing Base & Headquarters Table 12. Global α-Glucosidase Inhibitors Company, Product Type & Application Table 13. Global α-Glucosidase Inhibitors Company Establishment Date Table 14. Global Company Market Concentration Ratio (CR5 and HHI) Table 15. Global α-Glucosidase Inhibitors by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 16. Mergers & Acquisitions, Expansion Table 17. Significant Companies of Acarbose Table 18. Significant Companies of Voglibose Table 19. Significant Companies of Miglitol Table 20. Significant Companies of Other Table 21. Global α-Glucosidase Inhibitors Sales Volume by Type 2021 VS 2025 VS 2032 (K Units) Table 22. Global α-Glucosidase Inhibitors Sales Volume by Type (2021-2026) & (K Units) Table 23. Global α-Glucosidase Inhibitors Sales Volume by Type (2027-2032) & (K Units) Table 24. Global α-Glucosidase Inhibitors Sales Volume Share by Type (2021-2026) Table 25. Global α-Glucosidase Inhibitors Sales Volume Share by Type (2027-2032) Table 26. Global α-Glucosidase Inhibitors Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 27. Global α-Glucosidase Inhibitors Sales Value by Type (2021-2026) & (US$ Million) Table 28. Global α-Glucosidase Inhibitors Sales Value by Type (2027-2032) & (US$ Million) Table 29. Global α-Glucosidase Inhibitors Sales Value Share by Type (2021-2026) Table 30. Global α-Glucosidase Inhibitors Sales Value Share by Type (2027-2032) Table 31. Significant Companies of Hospital and Clinic Table 32. Significant Companies of Pharmacy Table 33. Significant Companies of Other Table 34. Global α-Glucosidase Inhibitors Sales Volume by Application 2021 VS 2025 VS 2032 (K Units) Table 35. Global α-Glucosidase Inhibitors Sales Volume by Application (2021-2026) & (K Units) Table 36. Global α-Glucosidase Inhibitors Sales Volume by Application (2027-2032) & (K Units) Table 37. Global α-Glucosidase Inhibitors Sales Volume Share by Application (2021-2026) Table 38. Global α-Glucosidase Inhibitors Sales Volume Share by Application (2027-2032) Table 39. Global α-Glucosidase Inhibitors Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 40. Global α-Glucosidase Inhibitors Sales Value by Application (2021-2026) & (US$ Million) Table 41. Global α-Glucosidase Inhibitors Sales Value by Application (2027-2032) & (US$ Million) Table 42. Global α-Glucosidase Inhibitors Sales Value Share by Application (2021-2026) Table 43. Global α-Glucosidase Inhibitors Sales Value Share by Application (2027-2032) Table 44. Global α-Glucosidase Inhibitors Sales by Region: 2021 VS 2025 VS 2032 (K Units) Table 45. Global α-Glucosidase Inhibitors Sales by Region (2021-2026) & (K Units) Table 46. Global α-Glucosidase Inhibitors Sales Market Share by Region (2021-2026) Table 47. Global α-Glucosidase Inhibitors Sales by Region (2027-2032) & (K Units) Table 48. Global α-Glucosidase Inhibitors Sales Market Share by Region (2027-2032) Table 49. Global α-Glucosidase Inhibitors Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 50. Global α-Glucosidase Inhibitors Sales Value by Region (2021-2026) & (US$ Million) Table 51. Global α-Glucosidase Inhibitors Sales Value Share by Region (2021-2026) Table 52. Global α-Glucosidase Inhibitors Sales Value by Region (2027-2032) & (US$ Million) Table 53. Global α-Glucosidase Inhibitors Sales Value Share by Region (2027-2032) Table 54. Global α-Glucosidase Inhibitors Market Average Price (US$/Unit) by Region (2021-2026) Table 55. Global α-Glucosidase Inhibitors Market Average Price (US$/Unit) by Region (2027-2032) Table 56. Global α-Glucosidase Inhibitors Sales by Country: 2021 VS 2025 VS 2032 (K Units) Table 57. Global α-Glucosidase Inhibitors Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 58. Global α-Glucosidase Inhibitors Sales by Country (2021-2026) & (K Units) Table 59. Global α-Glucosidase Inhibitors Sales Market Share by Country (2021-2026) Table 60. Global α-Glucosidase Inhibitors Sales by Country (2027-2032) & (K Units) Table 61. Global α-Glucosidase Inhibitors Sales Market Share by Country (2027-2032) Table 62. Global α-Glucosidase Inhibitors Sales Value by Country (2021-2026) & (US$ Million) Table 63. Global α-Glucosidase Inhibitors Sales Value Market Share by Country (2021-2026) Table 64. Global α-Glucosidase Inhibitors Sales Value by Country (2027-2032) & (US$ Million) Table 65. Global α-Glucosidase Inhibitors Sales Value Market Share by Country (2027-2032) Table 66. Bluepharma Company Information Table 67. Bluepharma Business Overview Table 68. Bluepharma α-Glucosidase Inhibitors Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 69. Bluepharma α-Glucosidase Inhibitors Product Portfolio Table 70. Bluepharma Recent Development Table 71. Glenmark Pharma Company Information Table 72. Glenmark Pharma Business Overview Table 73. Glenmark Pharma α-Glucosidase Inhibitors Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 74. Glenmark Pharma α-Glucosidase Inhibitors Product Portfolio Table 75. Glenmark Pharma Recent Development Table 76. Lunan Pharma Company Information Table 77. Lunan Pharma Business Overview Table 78. Lunan Pharma α-Glucosidase Inhibitors Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 79. Lunan Pharma α-Glucosidase Inhibitors Product Portfolio Table 80. Lunan Pharma Recent Development Table 81. Lupin Pharma Company Information Table 82. Lupin Pharma Business Overview Table 83. Lupin Pharma α-Glucosidase Inhibitors Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 84. Lupin Pharma α-Glucosidase Inhibitors Product Portfolio Table 85. Lupin Pharma Recent Development Table 86. Strides Pharma Company Information Table 87. Strides Pharma Business Overview Table 88. Strides Pharma α-Glucosidase Inhibitors Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 89. Strides Pharma α-Glucosidase Inhibitors Product Portfolio Table 90. Strides Pharma Recent Development Table 91. Bayer Company Information Table 92. Bayer Business Overview Table 93. Bayer α-Glucosidase Inhibitors Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 94. Bayer α-Glucosidase Inhibitors Product Portfolio Table 95. Bayer Recent Development Table 96. Beijing SL Pharmaceutical Company Information Table 97. Beijing SL Pharmaceutical Business Overview Table 98. Beijing SL Pharmaceutical α-Glucosidase Inhibitors Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 99. Beijing SL Pharmaceutical α-Glucosidase Inhibitors Product Portfolio Table 100. Beijing SL Pharmaceutical Recent Development Table 101. Cisen Pharmaceutical Company Information Table 102. Cisen Pharmaceutical Business Overview Table 103. Cisen Pharmaceutical α-Glucosidase Inhibitors Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 104. Cisen Pharmaceutical α-Glucosidase Inhibitors Product Portfolio Table 105. Cisen Pharmaceutical Recent Development Table 106. Hangzhou East China Pharmaceutical Company Information Table 107. Hangzhou East China Pharmaceutical Business Overview Table 108. Hangzhou East China Pharmaceutical α-Glucosidase Inhibitors Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 109. Hangzhou East China Pharmaceutical α-Glucosidase Inhibitors Product Portfolio Table 110. Hangzhou East China Pharmaceutical Recent Development Table 111. Pfizer Company Information Table 112. Pfizer Business Overview Table 113. Pfizer α-Glucosidase Inhibitors Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 114. Pfizer α-Glucosidase Inhibitors Product Portfolio Table 115. Pfizer Recent Development Table 116. Jinri Pharmaceutical (China) Company Information Table 117. Jinri Pharmaceutical (China) Business Overview Table 118. Jinri Pharmaceutical (China) α-Glucosidase Inhibitors Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 119. Jinri Pharmaceutical (China) α-Glucosidase Inhibitors Product Portfolio Table 120. Jinri Pharmaceutical (China) Recent Development Table 121. Livzon Pharm Company Information Table 122. Livzon Pharm Business Overview Table 123. Livzon Pharm α-Glucosidase Inhibitors Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 124. Livzon Pharm α-Glucosidase Inhibitors Product Portfolio Table 125. Livzon Pharm Recent Development Table 126. Luye Pharma Company Information Table 127. Luye Pharma Business Overview Table 128. Luye Pharma α-Glucosidase Inhibitors Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 129. Luye Pharma α-Glucosidase Inhibitors Product Portfolio Table 130. Luye Pharma Recent Development Table 131. Nanjing Hicin Pharmaceutical Company Information Table 132. Nanjing Hicin Pharmaceutical Business Overview Table 133. Nanjing Hicin Pharmaceutical α-Glucosidase Inhibitors Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 134. Nanjing Hicin Pharmaceutical α-Glucosidase Inhibitors Product Portfolio Table 135. Nanjing Hicin Pharmaceutical Recent Development Table 136. Shandong New Time Pharmaceutical Company Information Table 137. Shandong New Time Pharmaceutical Business Overview Table 138. Shandong New Time Pharmaceutical α-Glucosidase Inhibitors Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 139. Shandong New Time Pharmaceutical α-Glucosidase Inhibitors Product Portfolio Table 140. Shandong New Time Pharmaceutical Recent Development Table 141. CSPC Ouyi Pharmaceutical Company Information Table 142. CSPC Ouyi Pharmaceutical Business Overview Table 143. CSPC Ouyi Pharmaceutical α-Glucosidase Inhibitors Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 144. CSPC Ouyi Pharmaceutical α-Glucosidase Inhibitors Product Portfolio Table 145. CSPC Ouyi Pharmaceutical Recent Development Table 146. Weiao Pharmaceutical (Sichuan) Company Information Table 147. Weiao Pharmaceutical (Sichuan) Business Overview Table 148. Weiao Pharmaceutical (Sichuan) α-Glucosidase Inhibitors Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 149. Weiao Pharmaceutical (Sichuan) α-Glucosidase Inhibitors Product Portfolio Table 150. Weiao Pharmaceutical (Sichuan) Recent Development Table 151. Sun Pharmaceutical Company Information Table 152. Sun Pharmaceutical Business Overview Table 153. Sun Pharmaceutical α-Glucosidase Inhibitors Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 154. Sun Pharmaceutical α-Glucosidase Inhibitors Product Portfolio Table 155. Sun Pharmaceutical Recent Development Table 156. SUN Pharma Company Information Table 157. SUN Pharma Business Overview Table 158. SUN Pharma α-Glucosidase Inhibitors Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 159. SUN Pharma α-Glucosidase Inhibitors Product Portfolio Table 160. SUN Pharma Recent Development Table 161. Takeda Company Information Table 162. Takeda Business Overview Table 163. Takeda α-Glucosidase Inhibitors Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 164. Takeda α-Glucosidase Inhibitors Product Portfolio Table 165. Takeda Recent Development Table 166. YaoPharma Company Information Table 167. YaoPharma Business Overview Table 168. YaoPharma α-Glucosidase Inhibitors Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 169. YaoPharma α-Glucosidase Inhibitors Product Portfolio Table 170. YaoPharma Recent Development Table 171. Zhejiang Hisun Pharmaceutical Company Information Table 172. Zhejiang Hisun Pharmaceutical Business Overview Table 173. Zhejiang Hisun Pharmaceutical α-Glucosidase Inhibitors Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 174. Zhejiang Hisun Pharmaceutical α-Glucosidase Inhibitors Product Portfolio Table 175. Zhejiang Hisun Pharmaceutical Recent Development Table 176. Zhejiang Jingxin Pharmaceutical Company Information Table 177. Zhejiang Jingxin Pharmaceutical Business Overview Table 178. Zhejiang Jingxin Pharmaceutical α-Glucosidase Inhibitors Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 179. Zhejiang Jingxin Pharmaceutical α-Glucosidase Inhibitors Product Portfolio Table 180. Zhejiang Jingxin Pharmaceutical Recent Development Table 181. Zhejiang Medicine Company Information Table 182. Zhejiang Medicine Business Overview Table 183. Zhejiang Medicine α-Glucosidase Inhibitors Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 184. Zhejiang Medicine α-Glucosidase Inhibitors Product Portfolio Table 185. Zhejiang Medicine Recent Development Table 186. Key Raw Materials Table 187. Raw Materials Key Suppliers Table 188. α-Glucosidase Inhibitors Distributors List Table 189. α-Glucosidase Inhibitors Customers List Table 190. Research Programs/Design for This Report Table 191. Authors List of This Report Table 192. Secondary Sources Table 193. Primary Sources List of Figures Figure 1. α-Glucosidase Inhibitors Product Image Figure 2. Global α-Glucosidase Inhibitors Sales Value (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global α-Glucosidase Inhibitors Sales Value (2021-2032) & (US$ Million) Figure 4. Global α-Glucosidase Inhibitors Sales (2021-2032) & (K Units) Figure 5. Global α-Glucosidase Inhibitors Sales Average Price (US$/Unit) & (2021-2032) Figure 6. Global α-Glucosidase Inhibitors Company Revenue Ranking in 2025 (US$ Million) Figure 7. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 8. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 9. Acarbose Image Figure 10. Voglibose Image Figure 11. Miglitol Image Figure 12. Other Image Figure 13. Global α-Glucosidase Inhibitors Sales Volume by Type (2021 VS 2025 VS 2032) & (K Units) Figure 14. Global α-Glucosidase Inhibitors Sales Volume Share 2021 VS 2025 VS 2032 Figure 15. Global α-Glucosidase Inhibitors Sales Volume Share by Type (2021-2032) Figure 16. Global α-Glucosidase Inhibitors Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 17. Global α-Glucosidase Inhibitors Sales Value Share 2021 VS 2025 VS 2032 Figure 18. Global α-Glucosidase Inhibitors Sales Value Share by Type (2021-2032) Figure 19. Hospital and Clinic Image Figure 20. Pharmacy Image Figure 21. Other Image Figure 22. Global α-Glucosidase Inhibitors Sales Volume by Application (2021 VS 2025 VS 2032) & (K Units) Figure 23. Global α-Glucosidase Inhibitors Sales Volume Share 2021 VS 2025 VS 2032 Figure 24. Global α-Glucosidase Inhibitors Sales Volume Share by Application (2021-2032) Figure 25. Global α-Glucosidase Inhibitors Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 26. Global α-Glucosidase Inhibitors Sales Value Share 2021 VS 2025 VS 2032 Figure 27. Global α-Glucosidase Inhibitors Sales Value Share by Application (2021-2032) Figure 28. Global α-Glucosidase Inhibitors Sales by Region: 2021 VS 2025 VS 2032 (K Units) Figure 29. Global α-Glucosidase Inhibitors Sales Market Share by Region: 2021 VS 2025 VS 2032 Figure 30. Global α-Glucosidase Inhibitors Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 31. Global α-Glucosidase Inhibitors Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 32. North America α-Glucosidase Inhibitors Sales Value (2021-2032) & (US$ Million) Figure 33. North America α-Glucosidase Inhibitors Sales Value Share by Country (%), 2025 VS 2032 Figure 34. Europe α-Glucosidase Inhibitors Sales Value (2021-2032) & (US$ Million) Figure 35. Europe α-Glucosidase Inhibitors Sales Value Share by Country (%), 2025 VS 2032 Figure 36. Asia-Pacific α-Glucosidase Inhibitors Sales Value (2021-2032) & (US$ Million) Figure 37. Asia-Pacific α-Glucosidase Inhibitors Sales Value Share by Country (%), 2025 VS 2032 Figure 38. South America α-Glucosidase Inhibitors Sales Value (2021-2032) & (US$ Million) Figure 39. South America α-Glucosidase Inhibitors Sales Value Share by Country (%), 2025 VS 2032 Figure 40. Middle East & Africa α-Glucosidase Inhibitors Sales Value (2021-2032) & (US$ Million) Figure 41. Middle East & Africa α-Glucosidase Inhibitors Sales Value Share by Country (%), 2025 VS 2032 Figure 42. USA α-Glucosidase Inhibitors Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 43. USA α-Glucosidase Inhibitors Sales Value Share by Type, 2025 VS 2032 & (%) Figure 44. USA α-Glucosidase Inhibitors Sales Value Share by Application, 2025 VS 2032 & (%) Figure 45. Canada α-Glucosidase Inhibitors Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 46. Canada α-Glucosidase Inhibitors Sales Value Share by Type, 2025 VS 2032 & (%) Figure 47. Canada α-Glucosidase Inhibitors Sales Value Share by Application, 2025 VS 2032 & (%) Figure 48. Mexico α-Glucosidase Inhibitors Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 49. Mexico α-Glucosidase Inhibitors Sales Value Share by Type, 2025 VS 2032 & (%) Figure 50. Mexico α-Glucosidase Inhibitors Sales Value Share by Application, 2025 VS 2032 & (%) Figure 51. Germany α-Glucosidase Inhibitors Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 52. Germany α-Glucosidase Inhibitors Sales Value Share by Type, 2025 VS 2032 & (%) Figure 53. Germany α-Glucosidase Inhibitors Sales Value Share by Application, 2025 VS 2032 & (%) Figure 54. France α-Glucosidase Inhibitors Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 55. France α-Glucosidase Inhibitors Sales Value Share by Type, 2025 VS 2032 & (%) Figure 56. France α-Glucosidase Inhibitors Sales Value Share by Application, 2025 VS 2032 & (%) Figure 57. U.K. α-Glucosidase Inhibitors Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 58. U.K. α-Glucosidase Inhibitors Sales Value Share by Type, 2025 VS 2032 & (%) Figure 59. U.K. α-Glucosidase Inhibitors Sales Value Share by Application, 2025 VS 2032 & (%) Figure 60. Italy α-Glucosidase Inhibitors Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 61. Italy α-Glucosidase Inhibitors Sales Value Share by Type, 2025 VS 2032 & (%) Figure 62. Italy α-Glucosidase Inhibitors Sales Value Share by Application, 2025 VS 2032 & (%) Figure 63. Spain α-Glucosidase Inhibitors Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 64. Spain α-Glucosidase Inhibitors Sales Value Share by Type, 2025 VS 2032 & (%) Figure 65. Spain α-Glucosidase Inhibitors Sales Value Share by Application, 2025 VS 2032 & (%) Figure 66. Russia α-Glucosidase Inhibitors Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 67. Russia α-Glucosidase Inhibitors Sales Value Share by Type, 2025 VS 2032 & (%) Figure 68. Russia α-Glucosidase Inhibitors Sales Value Share by Application, 2025 VS 2032 & (%) Figure 69. Netherlands α-Glucosidase Inhibitors Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 70. Netherlands α-Glucosidase Inhibitors Sales Value Share by Type, 2025 VS 2032 & (%) Figure 71. Netherlands α-Glucosidase Inhibitors Sales Value Share by Application, 2025 VS 2032 & (%) Figure 72. Nordic Countries α-Glucosidase Inhibitors Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 73. Nordic Countries α-Glucosidase Inhibitors Sales Value Share by Type, 2025 VS 2032 & (%) Figure 74. Nordic Countries α-Glucosidase Inhibitors Sales Value Share by Application, 2025 VS 2032 & (%) Figure 75. China α-Glucosidase Inhibitors Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 76. China α-Glucosidase Inhibitors Sales Value Share by Type, 2025 VS 2032 & (%) Figure 77. China α-Glucosidase Inhibitors Sales Value Share by Application, 2025 VS 2032 & (%) Figure 78. Japan α-Glucosidase Inhibitors Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 79. Japan α-Glucosidase Inhibitors Sales Value Share by Type, 2025 VS 2032 & (%) Figure 80. Japan α-Glucosidase Inhibitors Sales Value Share by Application, 2025 VS 2032 & (%) Figure 81. South Korea α-Glucosidase Inhibitors Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 82. South Korea α-Glucosidase Inhibitors Sales Value Share by Type, 2025 VS 2032 & (%) Figure 83. South Korea α-Glucosidase Inhibitors Sales Value Share by Application, 2025 VS 2032 & (%) Figure 84. India α-Glucosidase Inhibitors Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 85. India α-Glucosidase Inhibitors Sales Value Share by Type, 2025 VS 2032 & (%) Figure 86. India α-Glucosidase Inhibitors Sales Value Share by Application, 2025 VS 2032 & (%) Figure 87. Australia α-Glucosidase Inhibitors Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 88. Australia α-Glucosidase Inhibitors Sales Value Share by Type, 2025 VS 2032 & (%) Figure 89. Australia α-Glucosidase Inhibitors Sales Value Share by Application, 2025 VS 2032 & (%) Figure 90. Southeast Asia α-Glucosidase Inhibitors Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 91. Southeast Asia α-Glucosidase Inhibitors Sales Value Share by Type, 2025 VS 2032 & (%) Figure 92. Southeast Asia α-Glucosidase Inhibitors Sales Value Share by Application, 2025 VS 2032 & (%) Figure 93. Brazil α-Glucosidase Inhibitors Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 94. Brazil α-Glucosidase Inhibitors Sales Value Share by Type, 2025 VS 2032 & (%) Figure 95. Brazil α-Glucosidase Inhibitors Sales Value Share by Application, 2025 VS 2032 & (%) Figure 96. Argentina α-Glucosidase Inhibitors Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 97. Argentina α-Glucosidase Inhibitors Sales Value Share by Type, 2025 VS 2032 & (%) Figure 98. Argentina α-Glucosidase Inhibitors Sales Value Share by Application, 2025 VS 2032 & (%) Figure 99. Chile α-Glucosidase Inhibitors Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 100. Chile α-Glucosidase Inhibitors Sales Value Share by Type, 2025 VS 2032 & (%) Figure 101. Chile α-Glucosidase Inhibitors Sales Value Share by Application, 2025 VS 2032 & (%) Figure 102. Colombia α-Glucosidase Inhibitors Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 103. Colombia α-Glucosidase Inhibitors Sales Value Share by Type, 2025 VS 2032 & (%) Figure 104. Colombia α-Glucosidase Inhibitors Sales Value Share by Application, 2025 VS 2032 & (%) Figure 105. Peru α-Glucosidase Inhibitors Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 106. Peru α-Glucosidase Inhibitors Sales Value Share by Type, 2025 VS 2032 & (%) Figure 107. Peru α-Glucosidase Inhibitors Sales Value Share by Application, 2025 VS 2032 & (%) Figure 108. Saudi Arabia α-Glucosidase Inhibitors Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 109. Saudi Arabia α-Glucosidase Inhibitors Sales Value Share by Type, 2025 VS 2032 & (%) Figure 110. Saudi Arabia α-Glucosidase Inhibitors Sales Value Share by Application, 2025 VS 2032 & (%) Figure 111. Israel α-Glucosidase Inhibitors Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 112. Israel Arabia α-Glucosidase Inhibitors Sales Value Share by Type, 2025 VS 2032 & (%) Figure 113. Israel Arabia α-Glucosidase Inhibitors Sales Value Share by Application, 2025 VS 2032 & (%) Figure 114. UAE α-Glucosidase Inhibitors Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 115. UAE α-Glucosidase Inhibitors Sales Value Share by Type, 2025 VS 2032 & (%) Figure 116. UAE α-Glucosidase Inhibitors Sales Value Share by Application, 2025 VS 2032 & (%) Figure 117. Turkey α-Glucosidase Inhibitors Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 118. Turkey α-Glucosidase Inhibitors Sales Value Share by Type, 2025 VS 2032 & (%) Figure 119. Turkey α-Glucosidase Inhibitors Sales Value Share by Application, 2025 VS 2032 & (%) Figure 120. Iran α-Glucosidase Inhibitors Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 121. Iran α-Glucosidase Inhibitors Sales Value Share by Type, 2025 VS 2032 & (%) Figure 122. Iran α-Glucosidase Inhibitors Sales Value Share by Application, 2025 VS 2032 & (%) Figure 123. Egypt α-Glucosidase Inhibitors Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 124. Egypt α-Glucosidase Inhibitors Sales Value Share by Type, 2025 VS 2032 & (%) Figure 125. Egypt α-Glucosidase Inhibitors Sales Value Share by Application, 2025 VS 2032 & (%) Figure 126. α-Glucosidase Inhibitors Value Chain Figure 127. Manufacturing Cost Structure Figure 128. α-Glucosidase Inhibitors Sales Mode & Process Figure 129. Direct Comparison with Distribution Share Figure 130. Distributors Profiles Figure 131. Years Considered Figure 132. Research Process Figure 133. Key Executives Interviewed

Scope & coverage.

Types
  • Acarbose
  • Voglibose
  • Miglitol
  • Other
Applications
  • Hospital and Clinic
  • Pharmacy
  • Other
Companies covered
  • Bluepharma
  • Glenmark Pharma
  • Lunan Pharma
  • Lupin Pharma
  • Strides Pharma
  • Bayer
  • Beijing SL Pharmaceutical
  • Cisen Pharmaceutical
  • Hangzhou East China Pharmaceutical
  • Pfizer
  • Jinri Pharmaceutical (China)
  • Livzon Pharm
  • Luye Pharma
  • Nanjing Hicin Pharmaceutical
  • Shandong New Time Pharmaceutical
  • CSPC Ouyi Pharmaceutical
  • Weiao Pharmaceutical (Sichuan)
  • Sun Pharmaceutical
  • SUN Pharma
  • Takeda
  • YaoPharma
  • Zhejiang Hisun Pharmaceutical
  • Zhejiang Jingxin Pharmaceutical
  • Zhejiang Medicine

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global α-Glucosidase Inhibitors Sales Value (2021-2032)
  4. 1.2.2 Global α-Glucosidase Inhibitors Sales Volume (2021-2032)
  5. 1.2.3 Global α-Glucosidase Inhibitors Sales Average Price (2021-2032)
  6. 1.3 Assumptions and Limitations
  7. 1.4 Study Goals and Objectives
2 α-Glucosidase Inhibitors Market Dynamics
  1. 2.1 α-Glucosidase Inhibitors Industry Trends
  2. 2.2 α-Glucosidase Inhibitors Industry Drivers
  3. 2.3 α-Glucosidase Inhibitors Industry Opportunities and Challenges
  4. 2.4 α-Glucosidase Inhibitors Industry Restraints
3 α-Glucosidase Inhibitors Market by Company
  1. 3.1 Global α-Glucosidase Inhibitors Company Revenue Ranking in 2025
  2. 3.2 Global α-Glucosidase Inhibitors Revenue by Company (2021-2026)
  3. 3.3 Global α-Glucosidase Inhibitors Sales Volume by Company (2021-2026)
  4. 3.4 Global α-Glucosidase Inhibitors Average Price by Company (2021-2026)
  5. 3.5 Global α-Glucosidase Inhibitors Company Ranking (2024-2026)
  6. 3.6 Global α-Glucosidase Inhibitors Company Manufacturing Base and Headquarters
  7. 3.7 Global α-Glucosidase Inhibitors Company Product Type and Application
  8. 3.8 Global α-Glucosidase Inhibitors Company Establishment Date
  9. 3.9 Market Competitive Analysis
  10. 3.9.1 Global α-Glucosidase Inhibitors Market Concentration Ratio (CR5 and HHI)
  11. 3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  12. 3.9.3 2025 α-Glucosidase Inhibitors Tier 1, Tier 2, and Tier 3 Companies
  13. 3.10 Mergers and Acquisitions Expansion
4 α-Glucosidase Inhibitors Market by Type
  1. 4.1 α-Glucosidase Inhibitors Type Introduction
  2. 4.1.1 Acarbose
  3. 4.1.2 Voglibose
  4. 4.1.3 Miglitol
  5. 4.1.4 Other
  6. 4.2 Global α-Glucosidase Inhibitors Sales Volume by Type
  7. 4.2.1 Global α-Glucosidase Inhibitors Sales Volume by Type (2021 VS 2025 VS 2032)
  8. 4.2.2 Global α-Glucosidase Inhibitors Sales Volume by Type (2021-2032)
  9. 4.2.3 Global α-Glucosidase Inhibitors Sales Volume Share by Type (2021-2032)
  10. 4.3 Global α-Glucosidase Inhibitors Sales Value by Type
  11. 4.3.1 Global α-Glucosidase Inhibitors Sales Value by Type (2021 VS 2025 VS 2032)
  12. 4.3.2 Global α-Glucosidase Inhibitors Sales Value by Type (2021-2032)
  13. 4.3.3 Global α-Glucosidase Inhibitors Sales Value Share by Type (2021-2032)
5 α-Glucosidase Inhibitors Market by Application
  1. 5.1 α-Glucosidase Inhibitors Application Introduction
  2. 5.1.1 Hospital and Clinic
  3. 5.1.2 Pharmacy
  4. 5.1.3 Other
  5. 5.2 Global α-Glucosidase Inhibitors Sales Volume by Application
  6. 5.2.1 Global α-Glucosidase Inhibitors Sales Volume by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global α-Glucosidase Inhibitors Sales Volume by Application (2021-2032)
  8. 5.2.3 Global α-Glucosidase Inhibitors Sales Volume Share by Application (2021-2032)
  9. 5.3 Global α-Glucosidase Inhibitors Sales Value by Application
  10. 5.3.1 Global α-Glucosidase Inhibitors Sales Value by Application (2021 VS 2025 VS 2032)
  11. 5.3.2 Global α-Glucosidase Inhibitors Sales Value by Application (2021-2032)
  12. 5.3.3 Global α-Glucosidase Inhibitors Sales Value Share by Application (2021-2032)
6 α-Glucosidase Inhibitors Regional Sales and Value Analysis
  1. 6.1 Global α-Glucosidase Inhibitors Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global α-Glucosidase Inhibitors Sales by Region (2021-2032)
  3. 6.2.1 Global α-Glucosidase Inhibitors Sales by Region: 2021-2026
  4. 6.2.2 Global α-Glucosidase Inhibitors Sales by Region (2027-2032)
  5. 6.3 Global α-Glucosidase Inhibitors Sales Value by Region: 2021 VS 2025 VS 2032
  6. 6.4 Global α-Glucosidase Inhibitors Sales Value by Region (2021-2032)
  7. 6.4.1 Global α-Glucosidase Inhibitors Sales Value by Region: 2021-2026
  8. 6.4.2 Global α-Glucosidase Inhibitors Sales Value by Region (2027-2032)
  9. 6.5 Global α-Glucosidase Inhibitors Market Price Analysis by Region (2021-2026)
  10. 6.6 North America
  11. 6.6.1 North America α-Glucosidase Inhibitors Sales Value (2021-2032)
  12. 6.6.2 North America α-Glucosidase Inhibitors Sales Value Share by Country, 2025 VS 2032
  13. 6.7 Europe
  14. 6.7.1 Europe α-Glucosidase Inhibitors Sales Value (2021-2032)
  15. 6.7.2 Europe α-Glucosidase Inhibitors Sales Value Share by Country, 2025 VS 2032
  16. 6.8 Asia-Pacific
  17. 6.8.1 Asia-Pacific α-Glucosidase Inhibitors Sales Value (2021-2032)
  18. 6.8.2 Asia-Pacific α-Glucosidase Inhibitors Sales Value Share by Country, 2025 VS 2032
  19. 6.9 South America
  20. 6.9.1 South America α-Glucosidase Inhibitors Sales Value (2021-2032)
  21. 6.9.2 South America α-Glucosidase Inhibitors Sales Value Share by Country, 2025 VS 2032
  22. 6.10 Middle East & Africa
  23. 6.10.1 Middle East & Africa α-Glucosidase Inhibitors Sales Value (2021-2032)
  24. 6.10.2 Middle East & Africa α-Glucosidase Inhibitors Sales Value Share by Country, 2025 VS 2032
7 α-Glucosidase Inhibitors Country-level Sales and Value Analysis
  1. 7.1 Global α-Glucosidase Inhibitors Sales by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global α-Glucosidase Inhibitors Sales Value by Country: 2021 VS 2025 VS 2032
  3. 7.3 Global α-Glucosidase Inhibitors Sales by Country (2021-2032)
  4. 7.3.1 Global α-Glucosidase Inhibitors Sales by Country (2021-2026)
  5. 7.3.2 Global α-Glucosidase Inhibitors Sales by Country (2027-2032)
  6. 7.4 Global α-Glucosidase Inhibitors Sales Value by Country (2021-2032)
  7. 7.4.1 Global α-Glucosidase Inhibitors Sales Value by Country (2021-2026)
  8. 7.4.2 Global α-Glucosidase Inhibitors Sales Value by Country (2027-2032)
  9. 7.5 USA
  10. 7.5.1 USA α-Glucosidase Inhibitors Sales Value Growth Rate (2021-2032)
  11. 7.5.2 USA α-Glucosidase Inhibitors Sales Value Share by Type, 2025 VS 2032
  12. 7.5.3 USA α-Glucosidase Inhibitors Sales Value Share by Application, 2025 VS 2032
  13. 7.6 Canada
  14. 7.6.1 Canada α-Glucosidase Inhibitors Sales Value Growth Rate (2021-2032)
  15. 7.6.2 Canada α-Glucosidase Inhibitors Sales Value Share by Type, 2025 VS 2032
  16. 7.6.3 Canada α-Glucosidase Inhibitors Sales Value Share by Application, 2025 VS 2032
  17. 7.7 Mexico
  18. 7.6.1 Mexico α-Glucosidase Inhibitors Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Mexico α-Glucosidase Inhibitors Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Mexico α-Glucosidase Inhibitors Sales Value Share by Application, 2025 VS 2032
  21. 7.8 Germany
  22. 7.8.1 Germany α-Glucosidase Inhibitors Sales Value Growth Rate (2021-2032)
  23. 7.8.2 Germany α-Glucosidase Inhibitors Sales Value Share by Type, 2025 VS 2032
  24. 7.8.3 Germany α-Glucosidase Inhibitors Sales Value Share by Application, 2025 VS 2032
  25. 7.9 France
  26. 7.9.1 France α-Glucosidase Inhibitors Sales Value Growth Rate (2021-2032)
  27. 7.9.2 France α-Glucosidase Inhibitors Sales Value Share by Type, 2025 VS 2032
  28. 7.9.3 France α-Glucosidase Inhibitors Sales Value Share by Application, 2025 VS 2032
  29. 7.10 U.K.
  30. 7.10.1 U.K. α-Glucosidase Inhibitors Sales Value Growth Rate (2021-2032)
  31. 7.10.2 U.K. α-Glucosidase Inhibitors Sales Value Share by Type, 2025 VS 2032
  32. 7.10.3 U.K. α-Glucosidase Inhibitors Sales Value Share by Application, 2025 VS 2032
  33. 7.11 Italy
  34. 7.11.1 Italy α-Glucosidase Inhibitors Sales Value Growth Rate (2021-2032)
  35. 7.11.2 Italy α-Glucosidase Inhibitors Sales Value Share by Type, 2025 VS 2032
  36. 7.11.3 Italy α-Glucosidase Inhibitors Sales Value Share by Application, 2025 VS 2032
  37. 7.12 Spain
  38. 7.12.1 Spain α-Glucosidase Inhibitors Sales Value Growth Rate (2021-2032)
  39. 7.12.2 Spain α-Glucosidase Inhibitors Sales Value Share by Type, 2025 VS 2032
  40. 7.12.3 Spain α-Glucosidase Inhibitors Sales Value Share by Application, 2025 VS 2032
  41. 7.13 Russia
  42. 7.13.1 Russia α-Glucosidase Inhibitors Sales Value Growth Rate (2021-2032)
  43. 7.13.2 Russia α-Glucosidase Inhibitors Sales Value Share by Type, 2025 VS 2032
  44. 7.13.3 Russia α-Glucosidase Inhibitors Sales Value Share by Application, 2025 VS 2032
  45. 7.14 Netherlands
  46. 7.14.1 Netherlands α-Glucosidase Inhibitors Sales Value Growth Rate (2021-2032)
  47. 7.14.2 Netherlands α-Glucosidase Inhibitors Sales Value Share by Type, 2025 VS 2032
  48. 7.14.3 Netherlands α-Glucosidase Inhibitors Sales Value Share by Application, 2025 VS 2032
  49. 7.15 Nordic Countries
  50. 7.15.1 Nordic Countries α-Glucosidase Inhibitors Sales Value Growth Rate (2021-2032)
  51. 7.15.2 Nordic Countries α-Glucosidase Inhibitors Sales Value Share by Type, 2025 VS 2032
  52. 7.15.3 Nordic Countries α-Glucosidase Inhibitors Sales Value Share by Application, 2025 VS 2032
  53. 7.16 China
  54. 7.16.1 China α-Glucosidase Inhibitors Sales Value Growth Rate (2021-2032)
  55. 7.16.2 China α-Glucosidase Inhibitors Sales Value Share by Type, 2025 VS 2032
  56. 7.16.3 China α-Glucosidase Inhibitors Sales Value Share by Application, 2025 VS 2032
  57. 7.17 Japan
  58. 7.17.1 Japan α-Glucosidase Inhibitors Sales Value Growth Rate (2021-2032)
  59. 7.17.2 Japan α-Glucosidase Inhibitors Sales Value Share by Type, 2025 VS 2032
  60. 7.17.3 Japan α-Glucosidase Inhibitors Sales Value Share by Application, 2025 VS 2032
  61. 7.18 South Korea
  62. 7.18.1 South Korea α-Glucosidase Inhibitors Sales Value Growth Rate (2021-2032)
  63. 7.18.2 South Korea α-Glucosidase Inhibitors Sales Value Share by Type, 2025 VS 2032
  64. 7.18.3 South Korea α-Glucosidase Inhibitors Sales Value Share by Application, 2025 VS 2032
  65. 7.19 India
  66. 7.19.1 India α-Glucosidase Inhibitors Sales Value Growth Rate (2021-2032)
  67. 7.19.2 India α-Glucosidase Inhibitors Sales Value Share by Type, 2025 VS 2032
  68. 7.19.3 India α-Glucosidase Inhibitors Sales Value Share by Application, 2025 VS 2032
  69. 7.20 Australia
  70. 7.20.1 Australia α-Glucosidase Inhibitors Sales Value Growth Rate (2021-2032)
  71. 7.20.2 Australia α-Glucosidase Inhibitors Sales Value Share by Type, 2025 VS 2032
  72. 7.20.3 Australia α-Glucosidase Inhibitors Sales Value Share by Application, 2025 VS 2032
  73. 7.21 Southeast Asia
  74. 7.21.1 Southeast Asia α-Glucosidase Inhibitors Sales Value Growth Rate (2021-2032)
  75. 7.21.2 Southeast Asia α-Glucosidase Inhibitors Sales Value Share by Type, 2025 VS 2032
  76. 7.21.3 Southeast Asia α-Glucosidase Inhibitors Sales Value Share by Application, 2025 VS 2032
  77. 7.22 Brazil
  78. 7.22.1 Brazil α-Glucosidase Inhibitors Sales Value Growth Rate (2021-2032)
  79. 7.22.2 Brazil α-Glucosidase Inhibitors Sales Value Share by Type, 2025 VS 2032
  80. 7.22.3 Brazil α-Glucosidase Inhibitors Sales Value Share by Application, 2025 VS 2032
  81. 7.23 Argentina
  82. 7.23.1 Argentina α-Glucosidase Inhibitors Sales Value Growth Rate (2021-2032)
  83. 7.23.2 Argentina α-Glucosidase Inhibitors Sales Value Share by Type, 2025 VS 2032
  84. 7.23.3 Argentina α-Glucosidase Inhibitors Sales Value Share by Application, 2025 VS 2032
  85. 7.24 Chile
  86. 7.24.1 Chile α-Glucosidase Inhibitors Sales Value Growth Rate (2021-2032)
  87. 7.24.2 Chile α-Glucosidase Inhibitors Sales Value Share by Type, 2025 VS 2032
  88. 7.24.3 Chile α-Glucosidase Inhibitors Sales Value Share by Application, 2025 VS 2032
  89. 7.25 Colombia
  90. 7.25.1 Colombia α-Glucosidase Inhibitors Sales Value Growth Rate (2021-2032)
  91. 7.25.2 Colombia α-Glucosidase Inhibitors Sales Value Share by Type, 2025 VS 2032
  92. 7.25.3 Colombia α-Glucosidase Inhibitors Sales Value Share by Application, 2025 VS 2032
  93. 7.26 Peru
  94. 7.26.1 Peru α-Glucosidase Inhibitors Sales Value Growth Rate (2021-2032)
  95. 7.26.2 Peru α-Glucosidase Inhibitors Sales Value Share by Type, 2025 VS 2032
  96. 7.26.3 Peru α-Glucosidase Inhibitors Sales Value Share by Application, 2025 VS 2032
  97. 7.27 Saudi Arabia
  98. 7.27.1 Saudi Arabia α-Glucosidase Inhibitors Sales Value Growth Rate (2021-2032)
  99. 7.27.2 Saudi Arabia α-Glucosidase Inhibitors Sales Value Share by Type, 2025 VS 2032
  100. 7.27.3 Saudi Arabia α-Glucosidase Inhibitors Sales Value Share by Application, 2025 VS 2032
  101. 7.28 Israel
  102. 7.28.1 Israel α-Glucosidase Inhibitors Sales Value Growth Rate (2021-2032)
  103. 7.28.2 Israel α-Glucosidase Inhibitors Sales Value Share by Type, 2025 VS 2032
  104. 7.28.3 Israel α-Glucosidase Inhibitors Sales Value Share by Application, 2025 VS 2032
  105. 7.29 UAE
  106. 7.29.1 UAE α-Glucosidase Inhibitors Sales Value Growth Rate (2021-2032)
  107. 7.29.2 UAE α-Glucosidase Inhibitors Sales Value Share by Type, 2025 VS 2032
  108. 7.29.3 UAE α-Glucosidase Inhibitors Sales Value Share by Application, 2025 VS 2032
  109. 7.30 Turkey
  110. 7.30.1 Turkey α-Glucosidase Inhibitors Sales Value Growth Rate (2021-2032)
  111. 7.30.2 Turkey α-Glucosidase Inhibitors Sales Value Share by Type, 2025 VS 2032
  112. 7.30.3 Turkey α-Glucosidase Inhibitors Sales Value Share by Application, 2025 VS 2032
  113. 7.31 Iran
  114. 7.31.1 Iran α-Glucosidase Inhibitors Sales Value Growth Rate (2021-2032)
  115. 7.31.2 Iran α-Glucosidase Inhibitors Sales Value Share by Type, 2025 VS 2032
  116. 7.31.3 Iran α-Glucosidase Inhibitors Sales Value Share by Application, 2025 VS 2032
  117. 7.32 Egypt
  118. 7.32.1 Egypt α-Glucosidase Inhibitors Sales Value Growth Rate (2021-2032)
  119. 7.32.2 Egypt α-Glucosidase Inhibitors Sales Value Share by Type, 2025 VS 2032
  120. 7.32.3 Egypt α-Glucosidase Inhibitors Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Bluepharma
  2. 8.1.1 Bluepharma Company Information
  3. 8.1.2 Bluepharma Business Overview
  4. 8.1.3 Bluepharma α-Glucosidase Inhibitors Sales, Value and Gross Margin (2021-2026)
  5. 8.1.4 Bluepharma α-Glucosidase Inhibitors Product Portfolio
  6. 8.1.5 Bluepharma Recent Developments
  7. 8.2 Glenmark Pharma
  8. 8.2.1 Glenmark Pharma Company Information
  9. 8.2.2 Glenmark Pharma Business Overview
  10. 8.2.3 Glenmark Pharma α-Glucosidase Inhibitors Sales, Value and Gross Margin (2021-2026)
  11. 8.2.4 Glenmark Pharma α-Glucosidase Inhibitors Product Portfolio
  12. 8.2.5 Glenmark Pharma Recent Developments
  13. 8.3 Lunan Pharma
  14. 8.3.1 Lunan Pharma Company Information
  15. 8.3.2 Lunan Pharma Business Overview
  16. 8.3.3 Lunan Pharma α-Glucosidase Inhibitors Sales, Value and Gross Margin (2021-2026)
  17. 8.3.4 Lunan Pharma α-Glucosidase Inhibitors Product Portfolio
  18. 8.3.5 Lunan Pharma Recent Developments
  19. 8.4 Lupin Pharma
  20. 8.4.1 Lupin Pharma Company Information
  21. 8.4.2 Lupin Pharma Business Overview
  22. 8.4.3 Lupin Pharma α-Glucosidase Inhibitors Sales, Value and Gross Margin (2021-2026)
  23. 8.4.4 Lupin Pharma α-Glucosidase Inhibitors Product Portfolio
  24. 8.4.5 Lupin Pharma Recent Developments
  25. 8.5 Strides Pharma
  26. 8.5.1 Strides Pharma Company Information
  27. 8.5.2 Strides Pharma Business Overview
  28. 8.5.3 Strides Pharma α-Glucosidase Inhibitors Sales, Value and Gross Margin (2021-2026)
  29. 8.5.4 Strides Pharma α-Glucosidase Inhibitors Product Portfolio
  30. 8.5.5 Strides Pharma Recent Developments
  31. 8.6 Bayer
  32. 8.6.1 Bayer Company Information
  33. 8.6.2 Bayer Business Overview
  34. 8.6.3 Bayer α-Glucosidase Inhibitors Sales, Value and Gross Margin (2021-2026)
  35. 8.6.4 Bayer α-Glucosidase Inhibitors Product Portfolio
  36. 8.6.5 Bayer Recent Developments
  37. 8.7 Beijing SL Pharmaceutical
  38. 8.7.1 Beijing SL Pharmaceutical Company Information
  39. 8.7.2 Beijing SL Pharmaceutical Business Overview
  40. 8.7.3 Beijing SL Pharmaceutical α-Glucosidase Inhibitors Sales, Value and Gross Margin (2021-2026)
  41. 8.7.4 Beijing SL Pharmaceutical α-Glucosidase Inhibitors Product Portfolio
  42. 8.7.5 Beijing SL Pharmaceutical Recent Developments
  43. 8.8 Cisen Pharmaceutical
  44. 8.8.1 Cisen Pharmaceutical Company Information
  45. 8.8.2 Cisen Pharmaceutical Business Overview
  46. 8.8.3 Cisen Pharmaceutical α-Glucosidase Inhibitors Sales, Value and Gross Margin (2021-2026)
  47. 8.8.4 Cisen Pharmaceutical α-Glucosidase Inhibitors Product Portfolio
  48. 8.8.5 Cisen Pharmaceutical Recent Developments
  49. 8.9 Hangzhou East China Pharmaceutical
  50. 8.9.1 Hangzhou East China Pharmaceutical Company Information
  51. 8.9.2 Hangzhou East China Pharmaceutical Business Overview
  52. 8.9.3 Hangzhou East China Pharmaceutical α-Glucosidase Inhibitors Sales, Value and Gross Margin (2021-2026)
  53. 8.9.4 Hangzhou East China Pharmaceutical α-Glucosidase Inhibitors Product Portfolio
  54. 8.9.5 Hangzhou East China Pharmaceutical Recent Developments
  55. 8.10 Pfizer
  56. 8.10.1 Pfizer Company Information
  57. 8.10.2 Pfizer Business Overview
  58. 8.10.3 Pfizer α-Glucosidase Inhibitors Sales, Value and Gross Margin (2021-2026)
  59. 8.10.4 Pfizer α-Glucosidase Inhibitors Product Portfolio
  60. 8.10.5 Pfizer Recent Developments
  61. 8.11 Jinri Pharmaceutical (China)
  62. 8.11.1 Jinri Pharmaceutical (China) Company Information
  63. 8.11.2 Jinri Pharmaceutical (China) Business Overview
  64. 8.11.3 Jinri Pharmaceutical (China) α-Glucosidase Inhibitors Sales, Value and Gross Margin (2021-2026)
  65. 8.11.4 Jinri Pharmaceutical (China) α-Glucosidase Inhibitors Product Portfolio
  66. 8.11.5 Jinri Pharmaceutical (China) Recent Developments
  67. 8.12 Livzon Pharm
  68. 8.12.1 Livzon Pharm Company Information
  69. 8.12.2 Livzon Pharm Business Overview
  70. 8.12.3 Livzon Pharm α-Glucosidase Inhibitors Sales, Value and Gross Margin (2021-2026)
  71. 8.12.4 Livzon Pharm α-Glucosidase Inhibitors Product Portfolio
  72. 8.12.5 Livzon Pharm Recent Developments
  73. 8.13 Luye Pharma
  74. 8.13.1 Luye Pharma Company Information
  75. 8.13.2 Luye Pharma Business Overview
  76. 8.13.3 Luye Pharma α-Glucosidase Inhibitors Sales, Value and Gross Margin (2021-2026)
  77. 8.13.4 Luye Pharma α-Glucosidase Inhibitors Product Portfolio
  78. 8.13.5 Luye Pharma Recent Developments
  79. 8.14 Nanjing Hicin Pharmaceutical
  80. 8.14.1 Nanjing Hicin Pharmaceutical Company Information
  81. 8.14.2 Nanjing Hicin Pharmaceutical Business Overview
  82. 8.14.3 Nanjing Hicin Pharmaceutical α-Glucosidase Inhibitors Sales, Value and Gross Margin (2021-2026)
  83. 8.14.4 Nanjing Hicin Pharmaceutical α-Glucosidase Inhibitors Product Portfolio
  84. 8.14.5 Nanjing Hicin Pharmaceutical Recent Developments
  85. 8.15 Shandong New Time Pharmaceutical
  86. 8.15.1 Shandong New Time Pharmaceutical Company Information
  87. 8.15.2 Shandong New Time Pharmaceutical Business Overview
  88. 8.15.3 Shandong New Time Pharmaceutical α-Glucosidase Inhibitors Sales, Value and Gross Margin (2021-2026)
  89. 8.15.4 Shandong New Time Pharmaceutical α-Glucosidase Inhibitors Product Portfolio
  90. 8.15.5 Shandong New Time Pharmaceutical Recent Developments
  91. 8.16 CSPC Ouyi Pharmaceutical
  92. 8.16.1 CSPC Ouyi Pharmaceutical Company Information
  93. 8.16.2 CSPC Ouyi Pharmaceutical Business Overview
  94. 8.16.3 CSPC Ouyi Pharmaceutical α-Glucosidase Inhibitors Sales, Value and Gross Margin (2021-2026)
  95. 8.16.4 CSPC Ouyi Pharmaceutical α-Glucosidase Inhibitors Product Portfolio
  96. 8.16.5 CSPC Ouyi Pharmaceutical Recent Developments
  97. 8.17 Weiao Pharmaceutical (Sichuan)
  98. 8.17.1 Weiao Pharmaceutical (Sichuan) Company Information
  99. 8.17.2 Weiao Pharmaceutical (Sichuan) Business Overview
  100. 8.17.3 Weiao Pharmaceutical (Sichuan) α-Glucosidase Inhibitors Sales, Value and Gross Margin (2021-2026)
  101. 8.17.4 Weiao Pharmaceutical (Sichuan) α-Glucosidase Inhibitors Product Portfolio
  102. 8.17.5 Weiao Pharmaceutical (Sichuan) Recent Developments
  103. 8.18 Sun Pharmaceutical
  104. 8.18.1 Sun Pharmaceutical Company Information
  105. 8.18.2 Sun Pharmaceutical Business Overview
  106. 8.18.3 Sun Pharmaceutical α-Glucosidase Inhibitors Sales, Value and Gross Margin (2021-2026)
  107. 8.18.4 Sun Pharmaceutical α-Glucosidase Inhibitors Product Portfolio
  108. 8.18.5 Sun Pharmaceutical Recent Developments
  109. 8.19 SUN Pharma
  110. 8.19.1 SUN Pharma Company Information
  111. 8.19.2 SUN Pharma Business Overview
  112. 8.19.3 SUN Pharma α-Glucosidase Inhibitors Sales, Value and Gross Margin (2021-2026)
  113. 8.19.4 SUN Pharma α-Glucosidase Inhibitors Product Portfolio
  114. 8.19.5 SUN Pharma Recent Developments
  115. 8.20 Takeda
  116. 8.20.1 Takeda Company Information
  117. 8.20.2 Takeda Business Overview
  118. 8.20.3 Takeda α-Glucosidase Inhibitors Sales, Value and Gross Margin (2021-2026)
  119. 8.20.4 Takeda α-Glucosidase Inhibitors Product Portfolio
  120. 8.20.5 Takeda Recent Developments
  121. 8.21 YaoPharma
  122. 8.21.1 YaoPharma Company Information
  123. 8.21.2 YaoPharma Business Overview
  124. 8.21.3 YaoPharma α-Glucosidase Inhibitors Sales, Value and Gross Margin (2021-2026)
  125. 8.21.4 YaoPharma α-Glucosidase Inhibitors Product Portfolio
  126. 8.21.5 YaoPharma Recent Developments
  127. 8.22 Zhejiang Hisun Pharmaceutical
  128. 8.22.1 Zhejiang Hisun Pharmaceutical Company Information
  129. 8.22.2 Zhejiang Hisun Pharmaceutical Business Overview
  130. 8.22.3 Zhejiang Hisun Pharmaceutical α-Glucosidase Inhibitors Sales, Value and Gross Margin (2021-2026)
  131. 8.22.4 Zhejiang Hisun Pharmaceutical α-Glucosidase Inhibitors Product Portfolio
  132. 8.22.5 Zhejiang Hisun Pharmaceutical Recent Developments
  133. 8.23 Zhejiang Jingxin Pharmaceutical
  134. 8.23.1 Zhejiang Jingxin Pharmaceutical Company Information
  135. 8.23.2 Zhejiang Jingxin Pharmaceutical Business Overview
  136. 8.23.3 Zhejiang Jingxin Pharmaceutical α-Glucosidase Inhibitors Sales, Value and Gross Margin (2021-2026)
  137. 8.23.4 Zhejiang Jingxin Pharmaceutical α-Glucosidase Inhibitors Product Portfolio
  138. 8.23.5 Zhejiang Jingxin Pharmaceutical Recent Developments
  139. 8.24 Zhejiang Medicine
  140. 8.24.1 Zhejiang Medicine Company Information
  141. 8.24.2 Zhejiang Medicine Business Overview
  142. 8.24.3 Zhejiang Medicine α-Glucosidase Inhibitors Sales, Value and Gross Margin (2021-2026)
  143. 8.24.4 Zhejiang Medicine α-Glucosidase Inhibitors Product Portfolio
  144. 8.24.5 Zhejiang Medicine Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 α-Glucosidase Inhibitors Value Chain Analysis
  2. 9.1.1 α-Glucosidase Inhibitors Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 α-Glucosidase Inhibitors Sales Mode & Process
  6. 9.2 α-Glucosidase Inhibitors Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 α-Glucosidase Inhibitors Distributors
  9. 9.2.3 α-Glucosidase Inhibitors Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst